The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy

References

• Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–1617. doi:10.1056/NEJMra0901557
   PubMed Web of Science ®Google Scholar
• Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009;27:2269–2277. doi:10.1200/JCO.2008.19.7921
   PubMed Web of Science ®Google Scholar
• Russo S, Butler J, Ove R, Blackstock AW. Locally advanced pancreatic cancer: a review. Semin Oncol. 2007;34:327–334. doi:10.1053/j.seminoncol.2007.05.007
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Goldstein D, Renschler MF. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N Engl J Med. 2014;370:479–480.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of border line resectable and non-resectable pancreatic cancer. Ann Oncol. 2013;24:2484–2492. doi:10.1093/annonc/mdt239
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Tumor Study Group. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer. 1985;56(11):2563–2568. doi:10.1002/1097-0142(19851201)56:11<2563::AID-CNCR2820561104>3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Haksoyler V, Topkan E, Caronna R. Prognostic utility of Prechemoradiotherapy albumin-to-alkaline phosphatase ratio in unresectable locally advanced pancreatic carcinoma patients. Gastroenterol Res Pract. 2021;2021:6647145. doi:10.1155/2021/6647145
   PubMed Web of Science ®Google Scholar
• Yildirim BA, Özdemir Y, Colakoglu T, Topkan E. Impact of presence and degree of pretreatment weight loss in locally-advanced pancreatic cancer patients treated with definitive concurrent chemoradiotherapy. Pancreatology. 2016;16(4):599–604. doi:10.1016/j.pan.2016.03.006
   PubMed Web of Science ®Google Scholar
• Topkan E, Mertsoylu H, Ozdemir Y, et al. Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy. Cancer Manag Res. 2019;11:8807–8815. doi:10.2147/CMAR.S222297
   PubMed Web of Science ®Google Scholar
• Topkan E, Mertsoylu H, Kucuk A. Low systemic inflammation response index predicts good prognosis in locally advanced pancreatic carcinoma patients treated with concurrent chemoradiotherapy. Gastroenterol Res Pract. 2020;2020:5701949. doi:10.1155/2020/5701949
   PubMed Web of Science ®Google Scholar
• Goh BK, Tan YM, Thng CH, et al. How useful are clinical, biochemical, and cross-sectional imaging features in predicting potentially malignant or malignant cystic lesions of the pancreas? J Am Coll Surg. 2008;206:17–27. doi:10.1016/j.jamcollsurg.2007.06.312
   PubMed Web of Science ®Google Scholar
• Kajbafzadeh AM, Elmi A, Talab SS, Emami H, Esfahani SA, Saeedi P. Urinary and serum carbohydrate antigen 19-9 as a biomarker in ureteropelvic junction obstruction in children. J Urol. 2010;183:2353–2360. doi:10.1016/j.juro.2010.02.031
   PubMed Web of Science ®Google Scholar
• Dyckhoff G, Warta R, Gonnermann A, Plinkert PK, Flechtenmacher C, Volkmann M. Carbohydrate antigen 19-9 in saliva: possible preoperative marker of malignancy in parotid tumors. Otolaryngol Head Neck Surg. 2011;145:772–777. doi:10.1177/0194599811414512
   PubMed Web of Science ®Google Scholar
• Roy S, Dasgupta A, Kar K. Comparison of urinary and serum CA 19-9 as markers of early-stage urothelial carcinoma. Int Braz J Urol. 2013;39:631–638. doi:10.1590/S1677-5538.IBJU.2013.05.04
   PubMed Web of Science ®Google Scholar
• Kim S, Park BK, Seo JH, et al. Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases. Sci Rep. 2020;10:8820. doi:10.1038/s41598-020-65720-8
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–277. doi:10.1001/jama.297.3.267
   PubMed Web of Science ®Google Scholar
• Berger AC, Winter K, Hoffman JP, et al. Five-year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys. 2012;84(3):e291–e297. doi:10.1016/j.ijrobp.2012.04.035
   PubMed Web of Science ®Google Scholar
• Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9 - tumor marker: past, present, and future. World J Gastrointest Surg. 2020;12(12):468–490. doi:10.4240/wjgs.v12.i12.468
   PubMed Web of Science ®Google Scholar
• Xu P, Wang X, Qian J, Li Z, Yao J, Xu A. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma. Medicine (Baltimore). 2021;100(6):e24651. doi:10.1097/MD.0000000000024651
   PubMed Web of Science ®Google Scholar
• Kowalchuk RO, Lester SC, Graham RP, et al. Predicting Adverse pathologic features and clinical outcomes of resectable pancreas cancer with preoperative CA 19-9. Front Oncol. 2021;11:651119. doi:10.3389/fonc.2021.651119
   PubMed Web of Science ®Google Scholar
• Ye C, Sadula A, Ren S, et al. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. Cancer Chemother Pharmacol. 2020;86(6):731–740. doi:10.1007/s00280-020-04165-2
   PubMed Web of Science ®Google Scholar
• Liu H, Zenati MS, Rieser CJ, et al. CA19-9 change during neoadjuvant therapy may guide the need for additional adjuvant therapy following resected pancreatic cancer. Ann Surg Oncol. 2020;27(10):3950–3960. doi:10.1245/s10434-020-08468-9
   PubMed Web of Science ®Google Scholar
• Reni M, Peretti U, Zanon S, et al. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol. 2020;85(4):641–650. doi:10.1007/s00280-020-04047-7
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• MacDonald N. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J Support Oncol. 2007;5(4):157–162.
   PubMedGoogle Scholar
• Zambirinis CP, Pushalkar S, Saxena D, Miller G. Pancreatic cancer, inflammation, and microbiome. Cancer J. 2014;20(3):195–202. doi:10.1097/PPO.0000000000000045
   PubMed Web of Science ®Google Scholar
• Steele CW, Jamieson NB, Evans TRJ, et al. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer. 2013;108(5):997–1003. doi:10.1038/bjc.2013.24
   PubMed Web of Science ®Google Scholar
• Shimizu T, Taniguchi K, Asakuma M, et al. Lymphocyte-to-monocyte ratio and prognostic nutritional index predict poor prognosis in patients on chemotherapy for unresectable pancreatic cancer. Anticancer Res. 2019;39(4):2169–2176. doi:10.21873/anticanres.13331
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540. doi:10.1016/j.ctrv.2012.08.003
   PubMed Web of Science ®Google Scholar
• Yamada S, Fujii T, Yabusaki N, et al. Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow Prognostic Score is the most reliable parameter. Medicine (Baltimore). 2016;95(18):e3582. doi:10.1097/MD.0000000000003582
   PubMed Web of Science ®Google Scholar
• Xiao Y, Xie Z, Shao Z, et al. Prognostic value of post-diagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients. Medicine (Baltimore). 2017;96(50):e9247. doi:10.1097/MD.0000000000009247
   PubMed Web of Science ®Google Scholar
• Shirai Y, Shiba H, Haruki K, et al. Preoperative platelet-to-albumin ratio predicts prognosis of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Anticancer Res. 2017;37(2):787–793. doi:10.21873/anticanres.11378
   PubMed Web of Science ®Google Scholar
• Jomrich G, Gruber ES, Winkle D, et al. Systemic immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg. 2020;24(3):610–618. doi:10.1007/s11605-019-04187-z
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167. doi:10.1002/cncr.30057
   PubMed Web of Science ®Google Scholar
• Pacheco-Barcia V, Mondéjar Solís R, France T, et al. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology. 2020;20(2):254–264. doi:10.1016/j.pan.2019.12.010
   PubMed Web of Science ®Google Scholar
• Hammel P, Huguet F, van Laethem J, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–1853. doi:10.1001/jama.2016.4324
   PubMed Web of Science ®Google Scholar
• Ioka T, Furuse J, Fukutomi A, et al. Randomized Phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. Jpn J Clin Oncol. 2021;51(2):235–243. doi:10.1093/jjco/hyaa198
   PubMed Web of Science ®Google Scholar
• Choi SH, Park SW, Seong J. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiother Oncol. 2018;129(2):340–346. doi:10.1016/j.radonc.2018.08.006
   PubMed Web of Science ®Google Scholar
• Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24(18):2897–2902. doi:10.1200/JCO.2005.05.3934
   PubMed Web of Science ®Google Scholar
• Herreros-Villanueva M, Ruiz-Rebollo L, Montes M, et al. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort. Mol Biol Rep. 2020;47(3):1583–1588. doi:10.1007/s11033-020-05245-5
   PubMed Web of Science ®Google Scholar
• Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(23):5591–5596. doi:10.1242/jcs.116392
   PubMed Web of Science ®Google Scholar
• Yang S, Wang X, Contino G, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25(7):717–729. doi:10.1101/gad.2016111
   PubMed Web of Science ®Google Scholar
• Aghajan M, Li N, Karin M. Obesity, autophagy and the pathogenesis of liver and pancreatic cancers. J Gastroenterol Hepatol. 2012;27(Suppl 2):10–14. doi:10.1111/j.1440-1746.2011.07008.x
   PubMedGoogle Scholar
• Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946–958. doi:10.1002/bjs.10870
   PubMed Web of Science ®Google Scholar